IRIX Form 4: CFO Romeo Dizon Buys 1,500 Shares Total

Rhea-AI Filing Summary

Romeo R. Dizon, Chief Financial Officer of IRIDEX Corp (IRIX), reported two open-market purchases of company common stock on 08/15/2025. He acquired 1,000 shares at $1.1799 per share and 500 shares at $1.15 per share, bringing his total reported beneficial ownership to 39,245 shares following the transactions. The Form 4 was signed on behalf of Mr. Dizon by an attorney-in-fact on 08/18/2025. No derivative transactions or other material changes were reported in this filing.

Insights

Securities Analyst

TL;DR: Insider purchases were disclosed but are small in absolute size and do not by themselves indicate material change.

The filing documents two non-derivative purchases by the issuer's CFO on 08/15/2025: 1,000 shares at $1.1799 and 500 shares at $1.15, increasing his reported beneficial ownership to 39,245 shares. These are routine Section 16 disclosures of open-market purchases. The transaction sizes and prices shown are explicit in the filing and there are no derivative positions or other arrangements disclosed. From a reporting perspective this is a standard Form 4 update and appears procedural rather than materially impactful to enterprise valuation.

Corporate Governance Specialist

TL;DR: The Form 4 properly reports insider purchases; filing includes signature by attorney-in-fact and lists officer title.

The document identifies Romeo R. Dizon as the reporting person and notes his role as Chief Financial Officer. It discloses two purchase transactions on 08/15/2025 and shows the required signature block executed by an attorney-in-fact on 08/18/2025. There are no amendments, no indication of Rule 10b5-1 plans, and no indirect ownership changes recorded. Procedurally, the filing meets Section 16 disclosure requirements based on the content provided.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dizon Romeo R

(Last) (First) (Middle)

1212 TERRA BELLA AVENUE

(Street)

MOUNTAIN VIEW CA 94043

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IRIDEX CORP [ IRIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/15/2025		P		1,000	A	$1.1799	38,745	D
Common Stock	08/15/2025		P		500	A	$1.15	39,245	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Nilo De Castro, Attorney-in-fact for Romeo Dizon	08/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did IRIX insider Romeo R. Dizon report on Form 4?

He reported two open-market purchases on 08/15/2025: 1,000 shares at $1.1799 and 500 shares at $1.15.

How many IRIX shares does Romeo R. Dizon beneficially own after the reported trades?

He beneficially owned 39,245 shares following the reported transactions.

What is Romeo R. Dizon's role at IRIDEX Corp (IRIX) as stated in the filing?

He is listed as Chief Financial Officer on the Form 4.

When were the transactions and the Form 4 signature dated?

Transactions occurred on 08/15/2025 and the Form 4 was signed by an attorney-in-fact on 08/18/2025.

Did the Form 4 report any derivative securities or Rule 10b5-1 plans?

No derivatives or 10b5-1 plan indications are reported in the provided content.